Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Gian Life Care's FCF Margin % or its related term are showing as below:
BOM:542918'
s FCF Margin % Range Over the Past 10 Years
Min: -2.2 Med: 4.39 Max: 23.28
Current: 6.77
During the past 7 years, the highest FCF Margin % of Gian Life Care was 23.28%. The lowest was -2.20%. And the median was 4.39%.
BOM:542918's FCF Margin % is ranked better than 67.49% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.96
vs BOM:542918: 6.77
The historical data trend for Gian Life Care's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542918 vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Gian Life Care's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gian Life Care FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Gian Life Care's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Gian Life Care's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gian Life Care (BOM:542918) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gian Life Care and its competitors. According to the industry distribution chart, Gian Life Care ranks #66 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 32.5%.
Is Gian Life Care's FCF Margin % too high?
Gian Life Care's current FCF Margin % is 0.00%. Based on the distribution chart, Gian Life Care ranks #66 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Gian Life Care has a GF Score™ of 59/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Gian Life Care's FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Gian Life Care ranks #66 out of 203 companies for FCF Margin %. This puts Gian Life Care in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Gian Life Care and its competitors. Gian Life Care's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gian Life Care stock overvalued right now?
Based on GuruFocus' analysis, Gian Life Care (BOM:542918) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹5.88, compared to a current price of ₹4.91 — trading 16.5% below its estimated fair value. The current FCF Margin % is 0.00%. Gian Life Care's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Gian Life Care (BOM:542918), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gian Life Care (BOM:542918) Overvalued in 2026?
Based on GuruFocus' analysis, Gian Life Care stock appears to be undervalued.
The current stock price of ₹4.91 is trading 16.5% below its estimated GF Value™ of ₹5.88.
GuruFocus considers Gian Life Care to be Modestly Undervalued.
Key valuation signals for BOM:542918:
FCF Margin %: 0.00%
GF Value™: ₹5.88 vs. price of ₹4.91 (16.5% below fair value)
No single metric tells the full story. See the BOM:542918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gian Life Care Ltd is an Indian firm engaged in the business of providing diagnostic and related healthcare tests and services in Kanpur and nearby areas. The company provides a broad range of diagnostic and related healthcare tests and services such as patient diagnosis, prevention, and wellness diagnosis services to its patients and healthcare providers. Its customers include individual patients, hospitals, other healthcare providers, and corporate customers. Substantial revenue accrues from the Pathological Testing Fees. The company has only one operating segment namely, Laboratories Pathological Investigations.
59GF Score
Get the complete analysis for BOM:542918
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542918 has been successfully added to your 
